Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 5/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.31 |
| ▸ | KIT | P10721 | 1/20 | 0.31 |
| ▸ | TACR3 | P29371 | 1/20 | 0.31 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.30 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30553269 | 1.00 | MGLL (0.39) | MGLLCYP11B1CYP11B2TRPA1LMNA | |
| SCHEMBL25325375 | 0.85 | MGLL (0.44) | MGLLCYP11B1CYP11B2PAK1TRPV1 | |
| SCHEMBL30700257 | 0.85 | TRPA1 (0.39) | MGLLTRPA1TACR3PAK1SCD5 | |
| SCHEMBL25324067 | 0.83 | MGLL (0.41) | MGLLKIT | |
| SCHEMBL30699864 | 0.82 | TRPA1 (0.37) | TRPA1LMNATACR3PAK1L3MBTL1 | |
| SCHEMBL25327858 | 0.79 | MGLL (0.38) | MGLLCYP11B1CYP11B2 | |
| SCHEMBL30553263 | 0.79 | MGLL (0.38) | MGLLCYP11B1CYP11B2 | |
| SCHEMBL30553165 | 0.78 | TRPA1 (0.38) | MGLLCYP11B1CYP11B2TRPA1SMYD3 | |
| SCHEMBL25325473 | 0.78 | TRPA1 (0.38) | MGLLCYP11B1CYP11B2TRPA1SMYD3 | |
| SCHEMBL30699861 | 0.78 | MGLL (0.40) | MGLLKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | claimed |
| WO-2023144160-A1 | NEW HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-03 | — | — | WO | claimed |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| WO-2023144160-A1 | NEW HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | MGLL 3523/4885CYP11B1 120/4885CYP11B2 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.